CLDI insider transaction filings
Calidi Biotherapeutics, Inc. — 48 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-19. Screen CLDI transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 8 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Fernandez Santidrian Antonio — Chief Scientific Officer | 1 | — | — | 1 |
| Jackson Andrew C. — Chief Financial Officer | 1 | — | — | 1 |
| Leftwich Scott — Director | 1 | — | — | 1 |
| Peoples George — Director | 1 | — | — | 1 |
| Poma Eric E — Chief Executive Officer | 1 | — | — | 1 |
| Sanders Corazon (Corsee) D. — Director | 1 | — | — | 1 |
| Schoeneck James A — Director | 1 | — | — | 1 |
| Stewart Alan R. — Director | 1 | — | — | 1 |
Recent Form 4 filings — Calidi Biotherapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Schoeneck James A — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Jackson Andrew C. — Chief Financial Officer | Grant/award (A): 14,000 (derivative) | EDGAR |
| 2026-08-19 | 4 | Stewart Alan R. — Director | Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Leftwich Scott — Director | Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Peoples George — Director | Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Sanders Corazon (Corsee) D. — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Fernandez Santidrian Antonio — Chief Scientific Officer | Grant/award (A): 16,000 (derivative) | EDGAR |
| 2026-08-19 | 4 | Poma Eric E — Chief Executive Officer | Grant/award (A): 32,000 (derivative) | EDGAR |
| 2025-12-16 | 4 | Camaisa Allan — Director | Sale (S): 850 @ $1.46 | EDGAR |
| 2025-09-05 | 4 | Fernandez Santidrian Antonio — Chief Scientific Officer | Grant/award (A): 35,000 (derivative) | EDGAR |
| 2025-09-05 | 4 | Jackson Andrew C. — Chief Financial Officer | Grant/award (A): 30,000 (derivative) | EDGAR |
| 2025-09-05 | 4 | Poma Eric E — Chief Executive Officer | Grant/award (A): 10,000 (derivative) | EDGAR |
| 2025-08-25 | 4 | Leftwich Scott — Director | Purchase (P): 125,000 @ $2 · Purchase (P): 125,000 (derivative) | EDGAR |
| 2025-08-25 | 4 | Jackson Andrew C. — Chief Financial Officer | Purchase (P): 2,500 @ $2 · Purchase (P): 2,500 (derivative) | EDGAR |
| 2025-08-25 | 4 | Schoeneck James A — Director | Purchase (P): 75,000 @ $2 · Purchase (P): 75,000 (derivative) | EDGAR |
| 2025-08-25 | 4 | Poma Eric E — Chief Executive Officer, Director | Purchase (P): 25,000 @ $2 · Purchase (P): 25,000 (derivative) | EDGAR |
| 2025-07-15 | 4 | Peoples George — Director | Grant/award (A): 137,078 (derivative) @ $0 | EDGAR |
| 2025-07-15 | 4 | Leftwich Scott — Director | Grant/award (A): 137,078 (derivative) @ $0 | EDGAR |
| 2025-07-15 | 4 | Stewart Alan R. — Director | Grant/award (A): 137,078 (derivative) @ $0 | EDGAR |
| 2025-07-15 | 4 | Schoeneck James A — Director | Grant/award (A): 164,493 (derivative) @ $0 | EDGAR |
| 2025-04-25 | 4 | Poma Eric E — Chief Executive Officer, Director | Grant/award (A): 726,412 (derivative) | EDGAR |
| 2025-01-03 | 4 | Leftwich Scott — Director | Grant/award (A): 11,684 | EDGAR |
| 2025-01-03 | 4 | Stewart Alan R. — Director | Grant/award (A): 12,771 | EDGAR |
| 2024-12-18 | 4 | Camaisa Allan — CEO and Chairman of the Board, Director | Sale (S): 10,000 @ $1.62 | EDGAR |
| 2024-10-15 | 4 | Peoples George — Director | Grant/award (A): 20,217 (derivative) | EDGAR |
| 2024-10-15 | 4 | Leftwich Scott — Director | Grant/award (A): 20,217 (derivative) | EDGAR |
| 2024-10-15 | 4 | Stewart Alan R. — Director | Grant/award (A): 20,217 (derivative) | EDGAR |
| 2024-10-15 | 4 | Schoeneck James A — Director | Grant/award (A): 20,217 (derivative) | EDGAR |
| 2024-09-30 | 4 | Camaisa Allan — CEO and Chairman of the Board, Director, 10% owner | Grant/award (A): 70,155 @ $1.15 | EDGAR |
| 2024-07-11 | 4 | Peoples George — Director | Grant/award (A): 30,904 (derivative) | EDGAR |
| 2024-07-02 | 4 | Leftwich Scott — Director | Grant/award (A): 67,187 | EDGAR |
| 2024-07-02 | 4 | Leftwich Scott — Director | Grant/award (A): 23,783 | EDGAR |
| 2024-07-02 | 4 | Stewart Alan R. — Director | Grant/award (A): 73,437 | EDGAR |
| 2024-07-02 | 4 | Stewart Alan R. — Director | Grant/award (A): 25,995 | EDGAR |
| 2024-07-02 | 4 | Schoeneck James A — Director | Grant/award (A): 79,687 | EDGAR |
| 2024-07-02 | 4 | Schoeneck James A — Director | Grant/award (A): 28,207 | EDGAR |
| 2024-06-20 | 4 | Camaisa Allan — CEO and Chairman of the Board, Director, 10% owner | Grant/award (A): 40,000 (derivative) | EDGAR |
| 2024-06-20 | 4 | Minev Boris Radoslavov — Interim Chief Medical Officer | Grant/award (A): 31,360 (derivative) | EDGAR |
| 2024-06-20 | 4 | Campbell Wendy Pizarro — Chief Admin. and Legal Officer | Grant/award (A): 40,000 (derivative) · Grant/award (A): 60,000 (derivative) | EDGAR |
| 2024-06-20 | 4 | Jackson Andrew C. — Chief Financial Officer | Grant/award (A): 300,000 (derivative) | EDGAR |
| 2024-06-05 | 4 | Schoeneck James A — Director | Option exercise (M): 173,000 @ $0.20 · Option exercise (M): 375,000 @ $0.20 · Option exercise (M): 173,000 (derivative) · Option exercise (M): 173,000 (derivative) · Option exercise (M): 375,000 (derivative) · Option exercise (M): 375,000 (derivative) · +1 more | EDGAR |
| 2024-04-22 | 4 | Schoeneck James A — Director | Grant/award (A): 375,000 @ $0.40 · Grant/award (A): 375,000 (derivative) · Grant/award (A): 375,000 (derivative) · Grant/award (A): 375,000 (derivative) | EDGAR |
| 2024-01-04 | 4 | Leftwich Scott — Director | Grant/award (A): 8,958 @ $1.80 · Grant/award (A): 70,249 (derivative) | EDGAR |
| 2024-01-04 | 4 | Camaisa Allan — CEO, President and Chairman, Director, 10% owner | Grant/award (A): 100,000 (derivative) | EDGAR |
| 2024-01-04 | 4 | Stewart Alan R. — Director | Grant/award (A): 7,282 @ $1.80 | EDGAR |
| 2024-01-04 | 4 | Zulueta Alfonso G — Director | Grant/award (A): 5,644 @ $1.80 | EDGAR |
| 2024-01-04 | 4 | Schoeneck James A — Director | Grant/award (A): 10,625 @ $1.80 · Grant/award (A): 70,249 (derivative) | EDGAR |
| 2023-12-26 | 4 | Vecchiolla Thomas A. — Director | Grant/award (A): 7,709 @ $1.80 | EDGAR |
Recent 8-K events — Calidi Biotherapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CLDI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →